A study of determinants of pulmonary fibrosis in COVID-19 survivors.

Raj Kumar; Rajiv Garg; Surya Kant; S.K. Verma; Santosh Kumar; R.A.S. Kushwaha; Ajay Kumar Verma; Anand Srivastava; Darshan Kumar Bajaj; Ankita Mandal

doi:10.36948/ijfmr.2024.v06i04.26339

A study of determinants of pulmonary fibrosis in COVID-19 survivors.

Author(s)	Raj Kumar, Rajiv Garg, Surya Kant, S.K. Verma, Santosh Kumar, R.A.S. Kushwaha, Ajay Kumar Verma, Anand Srivastava, Darshan Kumar Bajaj, Ankita Mandal
Country	India
Abstract	The COVID-19 pandemic has mainly affected the lungs, including many other organs. Many of the patients later developed pulmonary fibrosis. This study was planned to determine the pulmonary fibrosis determinants in post-COVID survivors. Hospital-based, cross-sectional study done over one year. A pre-designed proforma was used to collect necessary information, and follow-up HRCT and other investigations were evaluated. Out of 87 patients, 41.3%(n=36) developed pulmonary fibrosis; the majority, i.e.,66.6%(n=24), were males. Most of them, 49.42%(n=43), belonged to the age group of 51-70 years, among which 48.83%(n=21) developed fibrosis. Among the study subjects, 57.47% (n=50) had different comorbidities, of which 52% (n=26) developed pulmonary fibrosis. The proportion of diabetes was 31/50, out of which 67.7% (n=21, p=0.036) developed pulmonary fibrosis, while 80% (n=4, p=0.014) of patients with thyroid disorders developed pulmonary fibrosis. A total of 27 patients were treated in ICU, out of which 66.67% (n=18) developed pulmonary fibrosis. Pulmonary fibrosis developed more when steroids were not used on 9/19, 47% (n=9), compared to those where steroids were used on 27/68, 39.7% (n=27). Most patients, i.e.,>90% fibrotic, had raised inflammatory markers. About half of the survivors had post-COVID-19 pulmonary fibrosis. This study emphasized the relationship between pulmonary fibrosis and many factors, such as age, comorbidities, ICU admission, steroid usage, inflammatory markers, and secondary infections.
Keywords	post-covid, pulmonary-fibrosis, comorbidities, inflammatory-marker.
Field	Medical / Pharmacy
Published In	Volume 6, Issue 4, July-August 2024
Published On	2024-08-24
Cite This	A study of determinants of pulmonary fibrosis in COVID-19 survivors. - Raj Kumar, Rajiv Garg, Surya Kant, S.K. Verma, Santosh Kumar, R.A.S. Kushwaha, Ajay Kumar Verma, Anand Srivastava, Darshan Kumar Bajaj, Ankita Mandal - IJFMR Volume 6, Issue 4, July-August 2024. DOI 10.36948/ijfmr.2024.v06i04.26339
DOI	https://doi.org/10.36948/ijfmr.2024.v06i04.26339
Short DOI	https://doi.org/gt8g6s

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 6 Cover Page Vol 6 Isu 5 Cover Page Vol 6 Isu 4

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

A study of determinants of pulmonary fibrosis in COVID-19 survivors.

Share this